{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:31:10Z","timestamp":1785205870709,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T00:00:00Z","timestamp":1303948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00535-011-0401-2","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T05:07:35Z","timestamp":1303880855000},"page":"717-723","source":"Crossref","is-referenced-by-count":5,"title":["Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration"],"prefix":"10.1007","volume":"46","author":[{"given":"Sheikh Mohammad Fazle","family":"Akbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maumn","family":"Al-Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,28]]},"reference":[{"key":"401_CR1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Lancet. Lancet. 2009;373:582\u201392.","journal-title":"Lancet"},{"key":"401_CR2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2006.01.070","volume":"130","author":"R Perrillo","year":"2006","unstructured":"Perrillo R. Hepatitis B virus replication\u00a0\u00d7\u00a0time equals trouble. Gastroenterology. 2006;130:989\u201391.","journal-title":"Gastroenterology"},{"key":"401_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507\u201339.","journal-title":"Hepatology."},{"issue":"Suppl 1","key":"401_CR4","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","volume":"48","author":"F Zoulim","year":"2008","unstructured":"Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48(Suppl 1):S2\u201319.","journal-title":"J Hepatol"},{"key":"401_CR5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/hep.510300113","volume":"30","author":"HL Janssen","year":"1999","unstructured":"Janssen HL, Gerken G, Carre\u00f1o V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European concerted action on viral hepatitis (EUROHEP). Hepatology. 1999;30:238\u201343.","journal-title":"Hepatology"},{"key":"401_CR6","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","volume":"351","author":"P Marcellin","year":"2004","unstructured":"Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206\u201317.","journal-title":"N Engl J Med"},{"key":"401_CR7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800\u20137.","journal-title":"N Engl J Med"},{"key":"401_CR8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","volume":"354","author":"CL Lai","year":"2006","unstructured":"Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011\u201320.","journal-title":"N Engl J Med"},{"key":"401_CR9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","volume":"129","author":"CL Lai","year":"2005","unstructured":"Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528\u201336.","journal-title":"Gastroenterology"},{"key":"401_CR10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","volume":"35","author":"YO Kweon","year":"2001","unstructured":"Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001;35:749\u201355.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"401_CR11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1478-3231.2008.01941.x","volume":"29","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl 1):100\u20137.","journal-title":"Liver Int"},{"key":"401_CR12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0168-8278(01)00005-8","volume":"34","author":"C Camma","year":"2001","unstructured":"Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34:593\u2013602.","journal-title":"J Hepatol"},{"key":"401_CR13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"401_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/hep.510290312","volume":"29","author":"SM Lin","year":"1999","unstructured":"Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971\u20135.","journal-title":"Hepatology."},{"key":"401_CR15","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"RG Gish","year":"2007","unstructured":"Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al. Entecavir therapy for up to 96\u00a0weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437\u201344.","journal-title":"Gastroenterology"},{"key":"401_CR16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0168-8278(05)80143-6","volume":"20","author":"JP Zarski","year":"1994","unstructured":"Zarski JP, Causse X, Cohard M, Cougnard J, Trepo C. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol. 1994;20:735\u201341.","journal-title":"J Hepatol"},{"key":"401_CR17","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.510260634","volume":"26","author":"P Lampertico","year":"1997","unstructured":"Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997;26:1621\u20135.","journal-title":"Hepatology."},{"key":"401_CR18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1440-1746.2010.06271.x","volume":"25","author":"RN Chien","year":"2010","unstructured":"Chien RN. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective. J Gastroenterol Hepatol. 2010;25:852\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"401_CR19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","volume":"51","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403\u20137.","journal-title":"J Hepatol"},{"key":"401_CR20","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1517\/14656560903005579","volume":"10","author":"SM Akbar","year":"2009","unstructured":"Akbar SM, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother. 2009;10:1605\u201314.","journal-title":"Expert Opin Pharmacother."},{"key":"401_CR21","first-page":"1","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. AASLD guidelines chronic hepatitis B: update 2009. Hepatology. 2009;50:1\u201336.","journal-title":"Hepatology."},{"key":"401_CR22","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227\u201342.","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"401_CR23","first-page":"262","volume":"22","author":"YF Liaw","year":"2008","unstructured":"Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;22:262\u201383.","journal-title":"Hepatol Int."},{"key":"401_CR24","first-page":"1","volume":"174","author":"TJ Wilt","year":"2008","unstructured":"Wilt TJ, Shamliyan T, Shaukat A, Taylor BC, MacDonald R, Yuan JM, et al. Management of chronic hepatitis B. Evid Rep Technol Assess (Full Rep). 2008;174:1\u2013671.","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"issue":"Suppl 5","key":"401_CR25","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/hep.22929","volume":"49","author":"BC Taylor","year":"2009","unstructured":"Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: a systematic review of evidence. Hepatology. 2009;49(Suppl 5):S85\u201395.","journal-title":"Hepatology"},{"key":"401_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-150-2-200901200-00101","volume":"150","author":"TA Shamliyan","year":"2009","unstructured":"Shamliyan TA, MacDonald R, Shaukat A, Taylor BC, Yuan JM, Johnson JR, et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111\u201324.","journal-title":"Ann Intern Med"},{"issue":"Suppl","key":"401_CR27","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1046\/j.1440-1746.2000.02097.x","volume":"15","author":"CM Chu","year":"2000","unstructured":"Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2000;15(Suppl):E25\u201330.","journal-title":"J Gastroenterol Hepatol"},{"key":"401_CR28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65\u201373.","journal-title":"JAMA."},{"key":"401_CR29","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3748\/wjg.14.1617","volume":"14","author":"GF Lu","year":"2008","unstructured":"Lu GF, Tang FA, Zheng PY, Yang PC, Qi YM. Entecavir up-regulates dendritic cell function in patients with chronic hepatitis B. World J Gastroenterol. 2008;14:1617\u201321.","journal-title":"World J Gastroenterol"},{"key":"401_CR30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/jhep.2001.23045","volume":"33","author":"C Boni","year":"2001","unstructured":"Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology. 2001;33:963\u201371.","journal-title":"Hepatology."},{"key":"401_CR31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2893.2010.01300.x","volume":"18","author":"SM Akbar","year":"2011","unstructured":"Akbar SM, Horiike N, Chen S, Michitaka K, Abe M, Hiasa Y, et al. Mechanism of restoration of immune responses of patients with chronic hepatitis B during lamivudine therapy: increased antigen processing and presentation by dendritic cells. J Viral Hepat. 2011;18:200\u20135.","journal-title":"J Viral Hepat."},{"key":"401_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-2007-979468","volume":"27","author":"B Rehermann","year":"2007","unstructured":"Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis. 2007;27:152\u201360.","journal-title":"Semin Liver Dis"},{"key":"401_CR33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1369-5274(00)00109-0","volume":"3","author":"A Bertoletti","year":"2000","unstructured":"Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Microbiol. 2000;3:387\u201392.","journal-title":"Curr Opin Microbiol."},{"key":"401_CR34","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.191.8.1269","volume":"191","author":"MK Maini","year":"2000","unstructured":"Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269\u201380.","journal-title":"J Exp Med"},{"key":"401_CR35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1472-8206.2004.00300.x","volume":"19","author":"D Sprengers","year":"2005","unstructured":"Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol. 2005;19:17\u201326.","journal-title":"Fundam Clin Pharmacol."},{"key":"401_CR36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/14760584.5.5.707","volume":"5","author":"S Pol","year":"2006","unstructured":"Pol S, Michel ML. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines. 2006;5:707\u201316.","journal-title":"Expert Rev Vaccines"},{"key":"401_CR37","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","volume":"25","author":"P Vandepapeli\u00e8re","year":"2007","unstructured":"Vandepapeli\u00e8re P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25:8585\u201397.","journal-title":"Vaccine."},{"issue":"Suppl","key":"401_CR38","first-page":"438A","volume":"52","author":"SM Akbar","year":"2010","unstructured":"Akbar SM, Al-Mahtab M, Rahman S, Aguilar JC, Onji M, Mishiro S. Therapeutic potential of a novel therapeutic vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) administered through mucosal and parenteral route in patients with chronic hepatitis B. Hepatology. 2010;52(Suppl):438A\u20139A.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-011-0401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-011-0401-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-011-0401-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T10:11:51Z","timestamp":1560161511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-011-0401-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,28]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s00535-011-0401-2","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,28]]}}}